Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Management of Severe Asthma in Children
TL;DR: Investigation into identifying predictors of treatment response and biomarkers that can lead to precision and personalized management for children with severe asthma is ongoing and will be imperative in determining the optimal treatment strategies for pediatric severe asthma.
Journal ArticleDOI
Economic Evaluation of Omalizumab in the Treatment of Severe AllergicAsthma in Adult Patients in Greece: A Cost Effectiveness Analysis ofClinical Trial and Real-Life Data
Venkateshwarlu Sonathi,Magdalini Hatzikou,Mary Geitona,Michael Baldwin,E. Panitti,Nikolaos Siafakas +5 more
TL;DR: Omalizumab appears to be a cost-effective treatment option for patients with severe asthma compared to ST in Greece, and this result is confirmed both with trial and real-world data.
Journal ArticleDOI
Recommendations for the use of bronchial thermoplasty in the management of severe asthma.
Keertan Dheda,Keertan Dheda,Coenraad F.N. Koegelenberg,Aliasgar Esmail,Aliasgar Esmail,Elvis M Irusen,Michael E. Wechsler,Robert Niven,E D Bateman,Kian Fan Chung,Kian Fan Chung +10 more
TL;DR: Recommendations for the management of severe asthma are provided, with an emphasis on the role of bronchial thermoplasty, and the use of BT is endorsed in patients with severe persistent asthma who remain uncontrolled despite optimal medical therapy as outlined in steps 4 and 5.
Journal ArticleDOI
Biologicals in the Treatment of Bronchial Asthma
I. Haasler,C. Taube +1 more
TL;DR: The most prominent effect of biological treatment is the reduction of acute exacerbations in patients with severe asthma, and antibodies against IL-5 receptor (Benralizumab), against the IL-4 receptor alpha chain (Dupilumab) are in advanced clinical development.
Dissertation
From sneeze to wheeze: Non-invasive studies on asthma and rhinitis
TL;DR: It was found that patients with asthma had a greater perception of the obstruction induced during methacholine challenge test compared to patients with rhinitis and bronchial hyperresponsiveness, and signs indicated a higher degree of peripheral airway involvement in the asthmatic group.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.